Join FibroGen for Part I of a virtual KOL investor event series featuring Andrew Ko, MD (University of California San Francisco (UCSF), UCSF’s Helen Diller Family Comprehensive Cancer Center) and Vincent Picozzi, MD, MMM (Virginia Mason Digestive Disease and Cancer Institutes, Virginia Mason Medical Center), who will discuss the unmet medical need and current treatment landscape for pancreatic cancer, as well as the clinical development program for pamrevlumab,* a potential first-in-class monoclonal antibody targeting connective tissue growth factor (CTGF) for pancreatic cancer treatment.

The event will include information on the mechanism of action of pamrevlumab as well as a review of the pre-clinical and Phase 1/2 data for pamrevlumab and the two ongoing trials: the innovative Precision Promise^SM Phase 2/3 trial being conducted by the Pancreatic Cancer Action Network (PanCAN) for metastatic pancreatic cancer, and the LAPIS Phase 3 trial in locally advanced pancreatic cancer.

A live question and answer will follow the formal presentations.

The second event in the series, to be scheduled at a later date, will include a review of the development program for FG-3246; a Phase 2 ready CD46 targeting antibody-drug conjugate (ADC) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

*Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.

This series is intended for investor audiences only.